Trials / Recruiting
RecruitingNCT04982276
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
A Multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK109 | Subjects will receive AK109 by intravenous administration. |
| DRUG | paclitaxel | Subjects will receive AK109 in combination with paclitaxel. |
| DRUG | paclitaxel | Subjects will receive AK104 and AK109 in combination with paclitaxel. |
| BIOLOGICAL | AK104 | Subjects will receive AK104 by intravenous administration. |
Timeline
- Start date
- 2021-08-23
- Primary completion
- 2025-12-30
- Completion
- 2027-01-31
- First posted
- 2021-07-29
- Last updated
- 2025-11-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04982276. Inclusion in this directory is not an endorsement.